GlassScriptPhysician profile
Jacob M Graham
NPI 1144517715
$6,800.60
in general payments reported to CMS, 2019-2025
62 companies · $2,462 in 2025
The $2,462 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $400 · 2022: $772 · 2023: $1,355 · 2024: $1,813 · 2025: $2,462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,343 · Education: $286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,343.17 |
| Education | $285.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $638.50 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Astellas Pharma US INC | $617.93 | 2021-2025 | Vyloy, Xospata, Xtandi |
| Janssen Biotech, INC. | $566.17 | 2021-2025 | Darzalex, Rybrevant, Tecvayli |
| Takeda Pharmaceuticals U.S.A., INC. | $408.74 | 2021-2025 | Iclusig, Fruzaqla, Ninlaro |
| Novartis Pharmaceuticals Corporation | $397.23 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $303.71 | 2022-2025 | Enhertu |
| Daiichi Sankyo INC. | $277.12 | 2024-2025 | Enhertu, Injectafer, Datroway |
| Pfizer INC. | $259.22 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $252.87 | 2024-2025 | Keytruda, Reblozyl, Welireg |
| Genentech USA, INC. | $246.04 | 2023-2025 | Venclexta, Polivy, Tecentriq |
| Exelixis INC. | $194.99 | 2024-2025 | Cabometyx |
| Celgene Corporation | $169.89 | 2024-2025 | Reblozyl, Opdualag |
| Adaptive Biotechnologies Corporation | $157.75 | 2023-2025 | Clonoseq |
| Sanofi-Aventis U.S. LLC | $155.19 | 2021-2023 | |
| Genzyme Corporation | $152.13 | 2021-2024 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.